Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11377179rdf:typepubmed:Citationlld:pubmed
pubmed-article:11377179lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C0086222lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C0205250lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C0449830lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C0205344lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C2827597lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C0912129lld:lifeskim
pubmed-article:11377179lifeskim:mentionsumls-concept:C1705733lld:lifeskim
pubmed-article:11377179pubmed:issue5lld:pubmed
pubmed-article:11377179pubmed:dateCreated2001-5-29lld:pubmed
pubmed-article:11377179pubmed:abstractTextEnantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane ((-)-BPAP), which is a highly potent and selective catecholaminergic activity enhancer (CAE) substance, are described. The synthetic approach consists of the coupling reaction of benzofuran with (R)-N-tosyl-2-propylazirizine or (R)-N-methoxy-N-methylnorvaliamide, followed by appropriate modifications of the resulting coupling products. As the results, (-)-BPAP turned out to have the R configuration, which was finally confirmed by X-ray crystallographic analysis.lld:pubmed
pubmed-article:11377179pubmed:languageenglld:pubmed
pubmed-article:11377179pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11377179pubmed:citationSubsetIMlld:pubmed
pubmed-article:11377179pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11377179pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11377179pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11377179pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11377179pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11377179pubmed:statusMEDLINElld:pubmed
pubmed-article:11377179pubmed:monthMaylld:pubmed
pubmed-article:11377179pubmed:issn0968-0896lld:pubmed
pubmed-article:11377179pubmed:authorpubmed-author:WatanabeMMlld:pubmed
pubmed-article:11377179pubmed:authorpubmed-author:OkaTTlld:pubmed
pubmed-article:11377179pubmed:authorpubmed-author:IshidaTTlld:pubmed
pubmed-article:11377179pubmed:authorpubmed-author:KnollJJlld:pubmed
pubmed-article:11377179pubmed:authorpubmed-author:AndoTTlld:pubmed
pubmed-article:11377179pubmed:authorpubmed-author:YonedaFFlld:pubmed
pubmed-article:11377179pubmed:authorpubmed-author:YasusaTTlld:pubmed
pubmed-article:11377179pubmed:issnTypePrintlld:pubmed
pubmed-article:11377179pubmed:volume9lld:pubmed
pubmed-article:11377179pubmed:ownerNLMlld:pubmed
pubmed-article:11377179pubmed:authorsCompleteYlld:pubmed
pubmed-article:11377179pubmed:pagination1213-9lld:pubmed
pubmed-article:11377179pubmed:meshHeadingpubmed-meshheading:11377179...lld:pubmed
pubmed-article:11377179pubmed:meshHeadingpubmed-meshheading:11377179...lld:pubmed
pubmed-article:11377179pubmed:meshHeadingpubmed-meshheading:11377179...lld:pubmed
pubmed-article:11377179pubmed:meshHeadingpubmed-meshheading:11377179...lld:pubmed
pubmed-article:11377179pubmed:meshHeadingpubmed-meshheading:11377179...lld:pubmed
pubmed-article:11377179pubmed:meshHeadingpubmed-meshheading:11377179...lld:pubmed
pubmed-article:11377179pubmed:meshHeadingpubmed-meshheading:11377179...lld:pubmed
pubmed-article:11377179pubmed:year2001lld:pubmed
pubmed-article:11377179pubmed:articleTitleEnantioselective synthesis and absolute configuration of (-)-1-(benzofuran-2-yl)-2-propylaminopentane, ((-)-BPAP), a highly potent and selective catecholaminergic activity enhancer.lld:pubmed
pubmed-article:11377179pubmed:affiliationResearch Institute, Fujimoto Pharmaceutical Corporation, 1-3-40, Nishiotsuka, Matsubara, Osaka 580-8503, Japan. soyaku@fujumoto-pharm.co.jplld:pubmed
pubmed-article:11377179pubmed:publicationTypeJournal Articlelld:pubmed